Analysts await Juno Therapeutics, Inc. (NASDAQ:JUNO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.67 EPS, down 52.24% or $0.35 from last year’s $-0.32 per share.

At the moment 10 analysts are watching Juno Therapeutics, Inc. (NASDAQ:JUNO), 4 rate it “Buy”, 4 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 7 analysts have a mean sales target of 11.84 million. For the quarter ending Sep-16, 7 analysts have a mean sales target of 4.59 million whilst for the year ending Dec-16, 10 analysts have a mean target of 35.50 million.

In terms of earnings per share, 8 analysts have a -0.43 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 8 analysts have a -0.52 EPS mean target and for the quarter ending Sep-16 there are 10 estimates of -1.74 EPS.

The biggest institutional shareholders in Juno Therapeutics, Inc. include Crestline Management LP which owns 26 million shares in the company valued at $1.13 B million. Crestline Investors Inc. is the second biggest holder with 17 million shares currently valued at 603.73 million whilst ARCH Venture Partners has 12 million shares valued at 507.96 million.

Total shares held by institutions as of the most recent company filings are 95,318,013 with a reported 4,981,341 bought and 1,220,833 sold. These holdings make up 91.43% of the company’s outstanding shares.

Currently insiders hold 5,968,374 shares in the business which makes up 5.74% of shares. The biggest holder currently is Mr. Hans E. Bishop who owns 2,650,609 shares (2.55% of those outstanding), whilst Dr. Mark W. Frohlich holds 919,583 (0.88% of shares outstanding) and Mr. Richard Klausner holds 870,799 (0.84% of shares outstanding).

The stock decreased 1.59% or $0.6 during the last trading session, hitting $44.00. Juno Therapeutics, Inc. (NASDAQ:JUNO) has fallen 17.95% over the past 6 months and is downtrending.